Nonalcoholic fatty liver disease and alcohol-related liver disease: From clinical aspects to pathophysiological insights
2
조회
0
다운로드
7
인용
0
참고문헌
키워드
초록
Two major causes of steatohepatitis are alcohol and metabolic syndrome. Although the underlying causes of alcoholrelated liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) differ, there are certain similarities in terms of the mode of disease progression and underlying pathophysiological mechanisms. Further, excessive alcohol consumption is often seen in patients with metabolic syndrome, and alcoholic hepatitis exacerbation by comorbidity with metabolic syndrome is an emerging clinical problem. There are certain ethnic differences in the development of both NAFLD and ALD. Especially, Asian populations tend to be more susceptible to NAFLD, and genetic polymorphisms in patatin-like phospholipase domain-containing 3 (PNPLA3) play a key role in both NAFLD and ALD. From the viewpoint of pathophysiology, cellular stress responses, including autophagy and endoplasmic reticulum (ER) stress, are involved in the development of cellular injury in steatohepatitis. Further, gutderived bacterial products and innate immune responses in the liver most likely play a profound role in the pathogenesis of both ALD and NASH. Though the recent progress in the treatment of viral hepatitis has reduced the prevalence of viral-related development of hepatocellular carcinoma (HCC), non-viral HCC is increasing. Alcohol and metabolic syndrome synergistically exacerbate progression of steatohepatitis, resulting in carcinogenesis. The gut-liver axis is a potential therapeutic and prophylactic target for steatohepatitis and subsequent carcinogenesis.
Abstract
Two major causes of steatohepatitis are alcohol and metabolic syndrome. Although the underlying causes of alcoholrelated liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) differ, there are certain similarities in terms of the mode of disease progression and underlying pathophysiological mechanisms. Further, excessive alcohol consumption is often seen in patients with metabolic syndrome, and alcoholic hepatitis exacerbation by comorbidity with metabolic syndrome is an emerging clinical problem. There are certain ethnic differences in the development of both NAFLD and ALD. Especially, Asian populations tend to be more susceptible to NAFLD, and genetic polymorphisms in patatin-like phospholipase domain-containing 3 (PNPLA3) play a key role in both NAFLD and ALD. From the viewpoint of pathophysiology, cellular stress responses, including autophagy and endoplasmic reticulum (ER) stress, are involved in the development of cellular injury in steatohepatitis. Further, gutderived bacterial products and innate immune responses in the liver most likely play a profound role in the pathogenesis of both ALD and NASH. Though the recent progress in the treatment of viral hepatitis has reduced the prevalence of viral-related development of hepatocellular carcinoma (HCC), non-viral HCC is increasing. Alcohol and metabolic syndrome synergistically exacerbate progression of steatohepatitis, resulting in carcinogenesis. The gut-liver axis is a potential therapeutic and prophylactic target for steatohepatitis and subsequent carcinogenesis.
참고문헌 (67)
- Angulo P, "Nonalcoholic fatty liver disease", N Engl J Med, 346, pp.1221~1231 (2002)
- Torres DM, "Diagnosis and therapy of nonalcoholic steatohepatitis", Gastroenterology, 134, pp.1682~1698 (2008)
- European Association for the Study of the Liver, "EASL clinical practice guidelines : management of alcohol-related liver disease", J Hepatol, 69, pp.154~181 (2018)
- Crabb DW, "Diagnosis and treatment of alcohol-associated liver diseases : 2019 practice guidance from the American Association for the Study of Liver Diseases", Hepatology, 71, pp.306~333 (2020)
- Eckel RH, "The metabolic syndrome", Lancet, 365, pp.1415~1428 (2005)
- Byrne CD, "NAFLD : a multisystem disease", J Hepatol, 62, pp.S47~S64 (2015)
- Chiang DJ, "The impact of obesity and metabolic syndrome on alcoholic liver disease", Clin Liver Dis, 18, pp.157~163 (2014)
- Cameron AJ, "The metabolic syndrome : prevalence in worldwide populations", Endocrinol Metab Clin North Am, 33, pp.351~375 (2004)
- Ford ES, "Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US", J Diabetes, 2, pp.180~193 (2010)
- Aguilar M, "Prevalence of the metabolic syndrome in the United States, 2003-2012", JAMA, 313, pp.1973~1974 (2015)
- Gu D, "Prevalence of the metabolic syndrome and overweight among adults in China", Lancet, 365, pp.1398~1405 (2005)
- Pan WH, "Epidemiology of metabolic syndrome in Asia", Asia Pac J Clin Nutr, 17(Suppl 1), pp.37~42 (2008)
- Lee CM, "Comparisons of metabolic syndrome definitions in four populations of the Asia-Pacific region", Metab Syndr Relat Disord, 6, pp.37~46 (2008)
- Gurka MJ, "An examination of sex and racial", ethnic differences in the metabolic syndrome among adults : a confirmatory factor analysis and a resulting continuous severity score, 2014, pp.63, 218~225
- Falkner B, "Prevalence of metabolic syndrome and obesity-associated hypertension in the racial ethnic minorities of the United States", Curr Hypertens Rep, 16, pp.449~ (2014)
- Farrell GC, "Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region?", J Gastroenterol Hepatol, 18, pp.124~138 (2003)
- Ching-Yeung Yu B, "Magnitude of nonalcoholic fatty liver disease : Eastern perspective", J Clin Exp Hepatol, 9, pp.491~496 (2019)
- Romero-Gómez M, "Treatment of NAFLD with diet, physical activity and exercise", J Hepatol, 67, pp.829~846 (2017)
- Gabriel AS, "The role of the Japanese traditional diet in healthy and sustainable dietary patterns around the world", Nutrients, 10, pp.173~ (2018)
- Kodama K, "Ethnic differences in the relationship between insulin sensitivity and insulin response : a systematic review and meta-analysis", Diabetes Care, 36, pp.1789~1796 (2013)
- 이은정, "Diabetes in Asians", Endocrinology and Metabolism, 30(3), pp.263~269 (2015), 대한내분비학회
- Liu CJ, "Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese", J Gastroenterol Hepatol, 27, pp.1555~1560 (2012)
- Liangpunsakul S, "Alcoholic liver disease in Asia, Europe, and North America", Gastroenterology, 150, pp.1786~1797 (2016)
- Wall TL, "Biology, genetics, and environment : underlying factors influencing alcohol metabolism", Alcohol Res, 38, pp.59~68 (2016)
- Eng MY, "ALDH2, ADH1B, and ADH1C genotypes in Asians : a literature review", Alcohol Res Health, 30, pp.22~27 (2007)
- O’Shea RS, "Alcoholic liver disease", Hepatology, 51, pp.307~328 (2010)
- Becker U, "Prediction of risk of liver disease by alcohol intake, sex, and age : a prospective population study", Hepatology, 23, pp.1025~1029 (1996)
- Kono H, "Gender differences in early alcohol-induced liver injury : role of CD14, NF-kappaB, and TNF-alpha", Am J Physiol Gastrointest Liver Physiol, 278, pp.G652~G661 (2000)
- Yin M, "Estrogen is involved in early alcohol-induced liver injury in a rat enteral feeding model", Hepatology, 31, pp.117~123 (2000)
- Kwo PY, "Gender differences in alcohol metabolism : relationship to liver volume and effect of adjusting for body mass", Gastroenterology, 115, pp.1552~1557 (1998)
- Dettling A, "Ethanol elimination rates in men and women in consideration of the calculated liver weight", Alcohol, 41, pp.415~420 (2007)
- Mishra A, "Epidemiology and natural history of nonalcoholic fatty liver disease", J Clin Exp Hepatol, 2, pp.135~144 (2012)
- Matsushita N, "Gender difference in NASH susceptibility : roles of hepatocyte Ikkβ and Sult1e1", PLoS One, 12, pp.e0181052~ (2017)
- Marin V, "An animal model for the juvenile non-alcoholic fatty liver disease and non-alcoholic steatohepatitis", PLoS One, 11, pp.e0158817~ (2016)
- Lonardo A, "Sex differences in nonalcoholic fatty liver disease : state of the art and identification of research gaps", Hepatology, 70, pp.1457~1469 (2019)
- Chen KL, "Estrogens and female liver health", Steroids, 133, pp.38~43 (2018)
- Schwimmer JB, "Heritability of nonalcoholic fatty liver disease", Gastroenterology, 136, pp.1585~1592 (2009)
- Romeo S, "Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease", Nat Genet, 40, pp.1461~1465 (2008)
- Chen LZ, "PNPLA3I148M variant in nonalcoholic fatty liver disease : demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis", World J Gastroenterol, 21, pp.794~802 (2015)
- Li X, "I148M variant of PNPLA3 confer increased risk for nonalcoholic fatty liver disease not only in European population, but also in Chinese population", Hepatology, 54, pp.2275~ (2011)
- Kawaguchi T, "Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese", PLoS One, 7, pp.e38322~ (2012)
- Lee SS, "Role of the PNPLA3 I148M polymorphism in nonalcoholic fatty liver disease and fibrosis in Korea", Dig Dis Sci, 59, pp.2967~2974 (2014)
- Park JH, "I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease", Liver Int, 35, pp.2537~2546 (2015)
- Anstee QM, "Genetic factors that affect risk of alcoholic and nonalcoholic fatty liver disease", Gastroenterology, 150, pp.1728~1744.e7 (2016)
- Buch S, "A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis", Nat Genet, 47, pp.1443~1448 (2015)
- Gao B, "Alcoholic liver disease : pathogenesis and new therapeutic targets", Gastroenterology, 141, pp.1572~1585 (2011)
- Madrigal-Matute J, "Regulation of liver metabolism by autophagy", Gastroenterology, 150, pp.328~339 (2016)
- Liu X, "Endoplasmic reticulum stress and liver diseases", Liver Res, 3, pp.55~64 (2019)
- Suzuki M, "The chemical chaperone 4-phenylbutyric acid prevents alcoholinduced liver injury in obese KK-Ay mice", Alcohol Clin Exp Res, 43, pp.617~627 (2019)
- Schnabl B, "Interactions between the intestinal microbiome and liver diseases", Gastroenterology, 146, pp.1513~1524 (2014)
- Chopyk DM, "Contribution of the intestinal microbiome and gut barrier to hepatic disorders", Gastroenterology, 159, pp.849~863 (2020)
- Szabo G, "Gut-liver axis in alcoholic liver disease", Gastroenterology, 148, pp.30~36 (2015)
- Kitagawa R, "Rifaximin prevents ethanol-induced liver injury in obese KK-Ay mice through modulation of small intestinal microbiota signature", Am J Physiol Gastrointest Liver Physiol, 317, pp.G707~G715 (2019)
- Chu H, "The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease", J Hepatol, 72, pp.391~400 (2020)
- Yang AM, "Intestinal fungi contribute to development of alcoholic liver disease", J Clin Invest, 127, pp.2829~2841 (2017)
- Gao B, "Liver natural killer and natural killer T cells : immunobiology and emerging roles in liver diseases", J Leukoc Biol, 86, pp.513~528 (2009)
- Heymann F, "Immunology in the liver--from homeostasis to disease", Nat Rev Gastroenterol Hepatol, 13, pp.88~110 (2016)
- Tateishi R, "A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan : 2011-2015 update", J Gastroenterol, 54, pp.367~376 (2019)
- Tokushige K, "Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease : multicenter survey", J Gastroenterol, 51, pp.586~596 (2016)
- Yoshimoto S, "Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome", Nature, 499, pp.97~101 (2013)
- Yu LX, "The gut microbiome and liver cancer : mechanisms and clinical translation", Nat Rev Gastroenterol Hepatol, 14, pp.527~539 (2017)
- Oze I, "Alcohol drinking and esophageal cancer risk : an evaluation based on a systematic review of epidemiologic evidence among the Japanese population", Jpn J Clin Oncol, 41, pp.677~692 (2011)
- Yokoyama A, "Genetic polymorphisms of alcohol and aldehyde dehydrogenases and risk for esophageal and head and neck cancers", Jpn J Clin Oncol, 33, pp.111~121 (2003)
- Singh S, "Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma : a systematic review and meta-analysis", Clin Gastroenterol Hepatol, 11, pp.1399~1412.e7 (2013)
- Go VL, "Alcohol and pancreatic cancer", Alcohol, 35, pp.205~211 (2005)
- Theodoratou E, "Nature, nurture, and cancer risks : genetic and nutritional contributions to cancer", Annu Rev Nutr, 37, pp.293~320 (2017)
- Marchesini G, "Adipose tissue-associated cancer risk: Is it the fat around the liver, or the fat inside the liver?", J Hepatol, 71, pp.1073~1075 (2019)